CBAY Stock Overview
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CymaBay Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.48 |
| 52 Week High | US$32.50 |
| 52 Week Low | US$7.26 |
| Beta | 0.32 |
| 1 Month Change | 0.87% |
| 3 Month Change | 40.67% |
| 1 Year Change | 262.91% |
| 3 Year Change | 607.63% |
| 5 Year Change | 147.94% |
| Change since IPO | 260.89% |
Recent News & Updates
Recent updates
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%
Feb 15
Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher
Dec 22CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?
Dec 28CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01
Aug 11Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?
Jul 13CymaBay: Long-Term Potential Based On Prior PBC Trial Results
Jun 27Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?
Mar 17Why I've Taken A 'Starter' Position In CymaBay Therapeutics
Jan 20Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?
Dec 03We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth
May 15We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely
Jan 29
CymaBay Therapeutics (CBAY) Presents At AASLD 2020 Conference- Slideshow
Nov 17CymaBay Is Clawing Back, Now We Just Need Pipeline Conversion
Nov 08CymaBay Therapeutics EPS in-line
Nov 05Shareholder Returns
| CBAY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.03% | -2.2% | -3.7% |
| 1Y | 262.9% | 11.6% | 20.5% |
Return vs Industry: CBAY exceeded the US Pharmaceuticals industry which returned 25.3% over the past year.
Return vs Market: CBAY exceeded the US Market which returned 31.2% over the past year.
Price Volatility
| CBAY volatility | |
|---|---|
| CBAY Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CBAY's share price has been volatile over the past 3 months.
Volatility Over Time: CBAY's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 101 | Sujal Shah | www.cymabay.com |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes.
CymaBay Therapeutics, Inc. Fundamentals Summary
| CBAY fundamental statistics | |
|---|---|
| Market cap | US$3.73b |
| Earnings (TTM) | -US$105.37m |
| Revenue (TTM) | US$31.07m |
120.0x
P/S Ratio-35.4x
P/E RatioIs CBAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBAY income statement (TTM) | |
|---|---|
| Revenue | US$31.07m |
| Cost of Revenue | US$80.80m |
| Gross Profit | -US$49.73m |
| Other Expenses | US$55.64m |
| Earnings | -US$105.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -160.03% |
| Net Profit Margin | -339.10% |
| Debt/Equity Ratio | 37.4% |
How did CBAY perform over the long term?
See historical performance and comparison